U.S., July 2 -- ClinicalTrials.gov registry received information related to the study (NCT07046494) titled 'Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder' on May 30.
Brief Summary: This is a clinical research study for an investigational drug called RAP-219 in participants with bipolar I disorder. This study is being conducted to determine if RAP-219 is safe and effective in participants experiencing mania associated with bipolar I disorder.
Study Start Date: July, 2025
Study Type: INTERVENTIONAL
Condition:
Bipolar 1 Disorder
Intervention:
DRUG: RAP-219
RAP-219 tablets administered orally, once daily for 21 days
OTHER: Placebo
Matching placebo tablets administered orally, once da...